Key Highlights

• Q3 2026 DAYBUE net sales reached US$140 million, up 39% year-over-year, driven by uptake of DAYBUE STIX and new patient starts

• Neuren upgraded its 2026 total income guidance from trofinetide to US$91-93 million, including a US$35 million milestone from DAYBU's German launch

• Shares of Neuren surged 17.49% to close at A$23.24 on 05 November 2026, the day the quarterly update was released

Neuren Pharmaceuticals(ASX:NEU) closed at A$23.24 on 05 November 2026, surging 17.49% in a session where the S&P/ASX 200 (XJO) gained 2.61% to close at 9,065.10, adding 230.60 points, and the S&P/ASX 200 Health Care index (XHJ) advanced 3.64%, adding 1,240.30 points to 35,329.10. Overnight Wall Street gains following the Democrats' decisive victory in the U.S. midterm elections supported equities broadly. Neuren's significant outperformance of both the broader market and the healthcare sector came on the same day the company released its Q3 2026 update showing accelerating DAYBUE sales and upgraded income guidance. Neuren is a biopharmaceutical company focused on developing therapies for serious neurological disorders, with its commercial income derived from royalties on DAYBUE (trofinetide), licensed to Acadia Pharmaceuticals.

Q3 DAYBUE Sales Accelerate to US$140 Million

Neuren's licensing partner, Acadia Pharmaceuticals (Nasdaq: ACAD), reported Q3 2026 net sales of DAYBUE of US$140 million, representing a 39% increase from Q3 2025 and a 12% sequential increase from Q2 2026. Sales growth was driven by the uptake of DAYBUE STIX by existing patients, as well as new patient starts and patient restarts. More than 50% of U.S. DAYBUE users are now on DAYBUE STIX, up from 40% at the end of Q2 2026.

Acadia also increased its full-year 2026 global net sales guidance for DAYBUE to US$505-520 million, up from the previous range of US$480-510 million. During Q3, a new U.S. Patent covering weight-banded dosing of trofinetide was allowed, extending patent protections for DAYBUE and DAYBUE STIX through March 2041.

Income Guidance Upgraded to US$91-93 Million

Neuren earned Q3 2026 Royalty income of US$16.4 million, up 51% from Q3 2025. The company upgraded its full-year 2026 total income guidance from trofinetide to US$91-93 million, up from the previous range of US$53-56 million. This increase reflects higher anticipated royalty income of US$56-58 million (previously US$53-56 million) plus a US$35 million milestone payment earned on the first commercial sale of DAYBU in Germany in October 2026.

European Launch Begins in Germany

DAYBU was launched commercially in Germany in October 2026, with patients already receiving treatment. The first commercial sale triggered a US$35 million milestone payment to Neuren under the European licence agreement. The agreement also entitles Neuren to tiered royalty rates of 17% on annual net sales up to US$150 million, 20% on sales between US$150 million and US$300 million, and 23% on sales above US$300 million, along with sales milestone payments of up to US$170 million in aggregate.

Japan Regulatory Filing Planned for 2027

Acadia has completed a Phase 3 study of trofinetide in Rett syndrome in Japan, with results described as consistent with the LAVENDER Phase 3 study and supportive of a planned regulatory filing. Acadia is pursuing a distribution partner ahead of a potential filing in 2027 and a launch in 2028, subject to regulatory approval.

About Neuren Pharmaceuticals

Neuren is an ASX-listed biopharmaceutical company focused on therapies for neurological disorders caused by genetic abnormalities or brain injury. DAYBUE (trofinetide) is approved for Rett syndrome in the U.S., EU, Canada, and Israel. Neuren has granted an exclusive worldwide licence to Acadia Pharmaceuticals for trofinetide. The company's investigational candidate, NNZ-2591 (ercanetide), is in Phase 3 clinical development for Phelan-McDermid syndrome and earlier-stage development for additional neurodevelopmental conditions.

Sector Context

The ASX healthcare sector posted broad gains on 05 November, with the XHJ index advancing 3.64%. Biopharmaceutical companies with revenue-generating Assets and positive clinical or commercial catalysts attracted particular interest in the risk-on session. Neuren's 17.49% gain made it one of the day's top performers within the healthcare sector.

Risks to Consider

Neuren's income is largely dependent on Acadia's commercialisation of DAYBUE, making it susceptible to Acadia's execution and market dynamics. The transition to DAYBUE STIX, while positive for patient uptake, introduces product lifecycle management considerations. Competitive therapies for Rett syndrome could emerge, and regulatory outcomes in Japan and additional European markets are not guaranteed. The tiered royalty structure means Neuren's income growth is tied to the trajectory of global trofinetide sales.

Catalysts on Watch

Further commercial expansion of DAYBU across additional European markets could trigger additional sales milestone payments. The planned regulatory filing in Japan in 2027 and potential launch in 2028 represent the next geographic expansion opportunity. Updates on the Phase 3 Koala trial for NNZ-2591 in Phelan-McDermid syndrome could diversify Neuren's pipeline beyond trofinetide. The trajectory of Q4 DAYBUE sales and whether full-year guidance is met or exceeded will also be closely monitored.

The Bigger Picture

Neuren's Q3 2026 update demonstrates accelerating commercial momentum for DAYBUE, with the 39% year-over-year sales growth and the German launch marking a transition from a predominantly U.S.-centred commercial profile toward a global Revenue base. The upgraded income guidance of US$91-93 million for 2026, more than a 60% increase from the original range, reflects both the underlying prescription growth and the European milestone. With Japan on the horizon for 2027-2028, Neuren's royalty income trajectory is expanding across multiple geographies.